The estimated Net Worth of Robert H. Horel is at least $835 mil dollars as of 29 December 2015. Robert Horel owns over 51,218 units of Neogenomics stock worth over $835,366 and over the last 10 years Robert sold NEO stock worth over $0.
Robert has made over 3 trades of the Neogenomics stock since 2014, according to the Form 4 filled with the SEC. Most recently Robert exercised 51,218 units of NEO stock worth $80,412 on 29 December 2015.
The largest trade Robert's ever made was exercising 62,893 units of Neogenomics stock on 18 December 2014 worth over $90,566. On average, Robert trades about 36,625 units every 94 days since 2014. As of 29 December 2015 Robert still owns at least 51,218 units of Neogenomics stock.
You can see the complete history of Robert Horel stock trades at the bottom of the page.
Robert's mailing address filed with the SEC is 12701 COMMONWEALTH DRIVE SUITE 9, , FORT MYERS, FL, US 33913.
Over the last 12 years, insiders at Neogenomics have traded over $310,374,253 worth of Neogenomics stock and bought 167,456 units worth $1,699,153 . The most active insiders traders include Electric Coge Medical Syste..., Oort Douglas M Van y Steven C Jones. On average, Neogenomics executives and independent directors trade stock every 23 days with the average trade being worth of $2,654,175. The most recent stock trade was executed by Alicia C Olivo on 15 August 2024, trading 1,040 units of NEO stock currently worth $16,692.
neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig
Neogenomics executives and other stock owners filed with the SEC include: